UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Operating revenue:
Personalized oncology solutions	$ 623	$ 459	$ 1,245	$ 1,377
Translational oncology solutions	1,760	999	4,158	2,187
Total operating revenue	2,383	1,458	5,403	3,564
Costs and operating expenses:
Cost of personalized oncology solutions	732	582	1,525	1,354
Cost of translational oncology solutions	698	475	1,576	1,174
Research and development	677	436	1,079	823
Sales and marketing	698	680	1,340	1,389
General and administrative	1,279	1,201	2,355	2,340
Total costs and operating expenses	4,084	3,374	7,875	7,080
Loss from operations	(1,701)	(1,916)	(2,472)	(3,516)
Other (expense) income:
Change in fair value of warrant liability	(585)	(52)	(2,048)	233
Other (expense)	(29)	(5)	(30)	(10)
Total other (expense) income	(614)	(57)	(2,078)	223
Loss before provision for income taxes	(2,315)	(1,973)	(4,550)	(3,293)
Provision for income taxes	3	1	6	4
Net loss	$ (2,318)	$ (1,974)	$ (4,556)	$ (3,297)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	$ (0.03)	$ (0.04)	$ (0.07)	$ (0.07)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	66,863,147	47,079,000	66,857,630	47,073,000